Ribbon Bio opened an early‑access program for its new cell‑free long DNA manufacturing process, offering linear constructs up to ~11 kb with reported average accuracy near 95% and guaranteed accuracy above 90% for early customers. The in‑vitro process yields DNA free of bacterial proteins and endotoxins, an advantage for cell and gene therapy and mRNA vaccine developers. Ribbon highlighted its MiroSynth platform evolution and said the cell‑free option should ease GMP translation and regulatory review. Pricing starts at roughly $0.35 per base pair for standard molecules, with higher tiers for difficult sequences. The launch responds to growing demand for long, complex synthetic DNA as therapies move from discovery to clinic, and it positions Ribbon as a supplier focused on reducing contamination risk in therapeutic manufacturing.